Tonix Pharmaceuticals Holding (TNXP) Receivables - Net (2023 - 2026)

Tonix Pharmaceuticals Holding has reported Receivables - Net for 4 years, with the latest figure at $11.8 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 408.84% year-over-year to $11.8 million in Q2 2026; TTM through Jun 2026 was $11.8 million, a 408.84% increase from a year earlier, with the FY2025 full-year figure at $6.3 million, up 70.27% from the prior year.
• Receivables - Net was $11.8 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $8.8 million in the prior quarter.
• The five-year high for Receivables - Net was $11.8 million in Q2 2026, with the low at $1.6 million in Q3 2023.
• Average Receivables - Net over 4 years is $4.8 million, with a median of $3.7 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net slumped 30.52% in 2025, then surged 408.84% in 2026.
• Over 4 years, Receivables - Net stood at $4.6 million in 2023, then decreased by 19.76% to $3.7 million in 2024, then jumped by 70.27% to $6.3 million in 2025, then surged by 88.25% to $11.8 million in 2026.
• The last three Receivables - Net figures came in at $11.8 million (Q2 2026), $8.8 million (Q1 2026), and $6.3 million (Q4 2025), per Business Quant data.